Endocrine Abstracts

We have identified a signature that predicts response to androgen deprivation therapy in localized prostate cancer, and are now using this signature as a stratification variable on biomarker-driven clinical trials. Following up on the Stand-Up-To-Cancer sequencing findings we design a large umbrella trial which will personalize therapy based on actionable genomic alterations in metastatic castration-resistant prostate cancer.

DOI: 10.1530/endoabs.42.IL12

Biographical details: Felix Feng is Associate Professor of Radiation Oncology, Urology, and Medicine and Vice Chair for Faculty Development and Director of Translational Research of the Department of Radiation, University of California at San Francisco. He received his undergraduate training from Stanford University, where he earned a degree in Biological Sciences and received a President’s Award for Academic Excellence. He then received his MD from Washington University in St. Louis, where he received numerous awards for his research and academic achievements. He then completed both a postdoctoral research fellowship and his residency in radiation oncology at the University of Michigan, and subsequently joined the faculty there. In addition to being the Director of the Division of Translational Genomics, Dr. Feng also co-led the multidisciplinary clinic for prostate cancer patients and served as Director of the Genitourinary Cancer Program within the Department of Radiation Oncology at the University of Michigan. In 2016 he was recruited to join the faculty at UCSF. Dr. Feng is a physician-scientist focused on clinical and translational research aimed at improving outcomes for patients with prostate cancer. His laboratory focuses on identifying and validating biomarkers associated with treatment resistance in prostate cancer patients, and overcoming radiation or hormone therapy resistance with targeted therapy.